Month: September 2020

NOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATESNESS-ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020.The experiments, performed at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel (the “Tel Aviv Sourasky Medical Centre”) were designed to evaluate, in vivo, the immune response to CorVax™. The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax™, composed of multiple signal peptides. These results further...

SANTA BARBARA, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) (“AppFolio” or the “Company”), a leading provider of cloud-based business software solutions, services and data analytics, today announced that it has entered into a definitive agreement to sell 100% of the equity interest of its wholly-owned subsidiary, MyCase, Inc., which provides legal practice and case management software solutions, to Funds advised by Apax Partners (the “Apax Funds” or “Apax”) for approximately $193 million in cash.Founded in 2010, MyCase is a leading cloud-based legal practice management software designed to help firms run efficiently from anywhere, provide an exceptional client experience, and easily track firm performance so that firms can reach their business goals. MyCase covers the entire client lifecycle with Lead...

Fort Worth, TX, Sept. 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — ADM Endeavors, Inc. (OTCQB: ADMQ) announced today that ten additional governmental entities have “piggybacked” onto the Company’s existing Tarrant County, Texas Work Uniform Contract within the last week, adding potential new revenue of approximately $5,000 each annually.“Our efforts to expand government customers are continuing to pay dividends for ADMQ and its Shareholders,” said CEO Marc Johnson. New customers include a high school band, a health center and elementary and middle schools. Mr. Johnson explained that because of the one-year uniform contract with Tarrant County, which commenced on July 1, 2020, the Company is now on a bid list for an additional 525 government entities throughout the State of Texas, all which can participate under this contract...

IRVING, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA) today announced that it has launched the healthcare industry’s first all-encompassing, cloud-based claims processing gateway. The platform – PCH Global – enables healthcare providers (physicians and other healthcare practitioners) to streamline submission of healthcare claims, and enables payers (health insurers) to more efficiently process claims and related payments. The real benefit of the platform is the expected reduction in claim denials, faster processing of payments to providers, and ultimately, a better healthcare experience for patients.PCH Global builds upon Exela’s dominant position in the healthcare automation market. According to Everest’s 2019 Healthcare Business Process Automation Solution PEAK Matrix™ Assessment, Exela...

GOLETA, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, has engaged investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.MZ Group will work closely with Resonant management to develop and implement a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community. The campaign will highlight Resonant’s immense opportunity to efficiently monetize the growth of 5G with its proprietary XBAR® RF Filter design and other unique solutions the Company enables with its ISN® software tools platform for the development...

 SOLO EVs Are Coming to the U.S. SoonVANCOUVER, British Columbia, Sept. 08, 2020 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles, today released the first photos and video footage of a behind-the-scenes look at current SOLO EV production vehicles on the assembly line. Completed vehicles are expected to hit U.S. market this fall. Last month ElectraMeccanica announced the commencement of production of the SOLO EV through its manufacturing partner and strategic investor, Zongshen Industrial Group (“Zongshen”). The Company has targeted late November/early December for initial deliveries to those on its pre-order list before ramping production to meet increasing demand. The first deliveries will be to early adopters/reservation...

Jacksonville, Florida, Sept. 08, 2020 (GLOBE NEWSWIRE) — Global Warming Solutions, Inc. (TICKER: GWSO) today announced that it will begin the process of uplisting to the OTCQB. With the completion of the filing of its required financial statements, the Company is now a step closer to become eligible to up list its stock to a senior exchange.“We have worked toward this for some time now, and our plans to up list demonstrates our commitment to our shareholders and in building a great company with great progress on the way. Our current and future shareholders should all be very pleased with this milestone development for the company,” stated Vladimir Vasilenko, CEO of Global Warming Solutions, Inc.The Company’s stock is trading on the OTC Markets under the “Current Information” tier of the OTC Pinks since...

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET.A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company’s website for two weeks following the live presentation.About ChemoCentryxChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered, targeted therapies....

MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at two upcoming investor conferences in September.The following are the details for the conferences.H.C. Wainwright 22nd Annual Global Investment ConferenceEvent: Fireside Chat Discussion and Q&ADate and Time: Monday, September 14, 2020 at 4:30 PM EDTOppenheimer Fall Healthcare Life Sciences & MedTech SummitEvent: Fireside Chat Discussion and Q&ADate and Time: Monday, September 21, 2020 at 2:30 PM EDTIn addition to the presentations, management will also...

BELTSVILLE, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15th at 4:15 pm Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases....